ABT-874
BiologicalSQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
NCT Number: NCT00710580
Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Site Reference ID/Investigator# 10605, Birmingham, Alabama, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
SQ injection 50 mg BIW
SQ placebo injections for ABT-874 and etanercept
Time frame: 12 Weeks
Time frame: 12 Weeks
Time frame: 12 Weeks
AbbVie (prior sponsor, Abbott)
Industry
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04718896
Moderate to Severe Plaque Psoriasis, Psoriasis
Indianapolis, Indiana, United States
View Trial DetailsNCT03412747
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Glendale, Arizona, United States
View Trial DetailsNCT07051538
Moderate to Severe Plaque Psoriasis
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT04566666
Moderate to Severe Plaque Psoriasis
Yuma, Arizona, United States
View Trial Details